IONIS PHARMACEUTICALS INC
IONSAPI behind this page
IONS Q1 2026 request
Playground key active
/api/financials?ticker=IONS&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 246,091 | 131,612 | +87.0% |
Show Product Lines breakouts |
|||
| Collaborative Agreement Revenue [Member] | 120,660 | 45,031 | +167.9% |
| Commercial Revenue [Member] | 107,810 | 76,168 | +41.5% |
| DAWNZERA Sales [Member] | 15,855 | — | — |
| Other Commercial Revenue [Member] | 6,532 | 5,715 | +14.3% |
| Other Royalties [Member] | 3,904 | 6,784 | -42.5% |
| Product | 42,955 | 6,287 | +583.2% |
| Research and Development Revenue [Member] | 138,281 | 55,444 | +149.4% |
| Royalty | 58,323 | 64,166 | -9.1% |
| SPINRAZA Royalties [Member] | 43,710 | 48,010 | -9.0% |
| TRYNGOLZA Sales [Member] | 27,100 | 6,287 | +331.0% |
| WAINUA Joint Development Revenue [Member] | 17,621 | 10,413 | +69.2% |
| WAINUA Royalties [Member] | 10,709 | 9,372 | +14.3% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | 246,091 | 131,612 | +87.0% |
Show Regulatory Agency breakouts |
|||
| MAA Accepted for Review by EMA [Member] · GSK [Member] | 15 | — | — |
| NDA Accepted for Review by MHLW [Member] · GSK [Member] | 15 | — | — |
Show Type Of Arrangement breakouts |
|||
| DAWNZERA [Member] | 15 | — | — |
| GSK [Member] | 30,000 | — | — |
| Otsuka [Member] | 19,932 | 6,528 | +205.3% |
| RNA-targeted Programs for AD and HD [Member] | 50 | — | — |
| Roche [Member] | 50,000 | 1,965 | +2444.5% |
| Cost of Revenue | 2,983 | 1,463 | +103.9% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | 2,836 | 1,363 | +108.1% |
| Total Costs & Expenses | 363,515 | 278,472 | +30.5% |
| Selling, General & Administrative | 150,359 | 76,250 | +97.2% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | 131,937 | 66,980 | +97.0% |
| Operating Income | -117,424 | -146,860 | +20.0% |
| Other Non-Operating Income (Expense) | -456 | 465 | -198.1% |
| Income Before Taxes | -92,310 | -146,822 | +37.1% |
| Income Tax Expense (Benefit) | -218 | -116 | -87.9% |
| Net Income | -92,528 | -146,938 | +37.0% |
Show Business Segments breakouts |
|||
| Ionis Operations [Member] | -92,528 | -146,938 | +37.0% |
Show Equity Components breakouts |
|||
| Retained Earnings | -92,528 | -146,938 | +37.0% |
| Comprehensive Income | -98,270 | -145,076 | +32.3% |
| EPS (Basic) | -0.56 | -0.93 | +39.8% |
| EPS (Diluted) | -0.56 | -0.93 | +39.8% |
| Wtd Avg Shares (Basic) | 164,874 | 158,735 | +3.9% |
| Wtd Avg Shares (Diluted) | 164,874 | 158,735 | +3.9% |
| Gain Loss On Investments | 22,583 | -2,164 | +1143.6% |
| Interest Expense | -5,160 | -4,108 | -25.6% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 173,381 | — | — |
| Short-Term Investments | 1,745,732 | — | — |
| Inventory | 5,557 | — | — |
| Total Current Assets | 2,936,945 | — | — |
| Non-Current Assets | |||
| Property, Plant & Equipment | 142,401 | — | — |
| Operating Lease Right-of-Use Assets | 235,064 | — | — |
| Other Non-Current Assets | 135,559 | — | — |
| Total Assets | 3,449,969 | — | — |
| Current Liabilities | |||
| Accounts Payable | 26,030 | — | — |
| Accrued Liabilities | 126,549 | — | — |
| Deferred Revenue (Current) | 69,199 | — | — |
| Total Current Liabilities | 716,591 | — | — |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 259,215 | — | — |
| Other Non-Current Liabilities | 28,274 | — | — |
| Total Liabilities | 2,958,555 | — | — |
| Contract With Customer Liability Noncurrent | 75,745 | — | — |
| Stockholders' Equity | |||
| Common Stock | 166 | — | — |
| Retained Earnings | -2,723,723 | — | — |
| Accumulated Other Comprehensive Income | -31,023 | — | — |
| Total Stockholders' Equity | 491,414 | 475,726 | +3.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -31,023 | -28,949 | -7.2% |
| Additional Paid In Capital | 3,245,994 | 2,901,262 | +11.9% |
| Common Stock | 166 | 159 | +4.4% |
| Retained Earnings | -2,723,723 | -2,396,746 | -13.6% |
| Total Liabilities & Equity | 3,449,969 | — | — |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 43,275 | 29,718 | +45.6% |
| Change in Inventory | 338 | 1,010 | -66.5% |
| Change in Accounts Payable | -3,095 | -25,968 | +88.1% |
| Change in Deferred Revenue | -20,818 | -13,718 | -51.8% |
| Net Cash from Operations | -792,819 | -150,775 | -425.8% |
| Investing Activities | |||
| Capital Expenditures | -21,763 | -12,577 | -73.0% |
| Purchases of Investments | -192,755 | -311,068 | +38.0% |
| Net Cash from Investing | 536,820 | 170,459 | +214.9% |
| Financing Activities | |||
| Amortization of Financing Costs | 2,349 | 1,642 | +43.1% |
| Net Cash from Financing | 57,258 | 2,199 | +2503.8% |
| Supplemental | |||
| Income Taxes Paid | -8 | -400 | +98.0% |
| Interest Paid | 90 | 92 | -2.2% |
| Other Cash Flow | |||
| Net Change in Cash | -198,879 | 22,115 | -999.3% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.